Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 19, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, April 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Kaplan Reiterated (TGTX) at Strong Buy and Held Target at $39 on, Apr 18th, 2024
Matthew Kaplan of Ladenburg Thalmann, Reiterated "TG Therapeutics, Inc." (TGTX) at Strong Buy and Held Target at $39 on, Apr 18th, 2024.
Matthew has made no other calls on TGTX in the last 4 months.
There are 2 other peers that have a rating on TGTX. Out of the 2 peers that are also analyzing TGTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $13 on, Thursday, February 29th, 2024
This is the rating of the analyst that currently disagrees with Matthew
- Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $29 on, Monday, February 5th, 2024
